eye disease: A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma. [NCIt:C26767]
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
301 |
4. Check minimum number of eventsNone |
301 |
5. Include endpointsNone |
301 |
6. Filter based on genotype QC (FinnGen only) |
301 |
Control definitions (FinnGen only)
- Control exclude
- H7_VITREOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H43
- Name in latin
- Depositiones crystallinae corporis vitrei
Similar endpoints
↥List of similar endpoints to
Crystalline deposits in vitreous body
based on the number of shared cases.
Similar with more cases:
- Disorders of vitreous body
- Disorders of vitreous body and globe
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1754 | 700 | 1049 |
| Only index persons | 1640 | 667 | 973 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.02 | 0.03 |
| Only index persons | 0.03 | 0.02 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 71.12 | 69.89 | 71.95 |
| Only index persons | 70.79 | 69.70 | 71.54 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 301 | 121 | 180 |
| Unadjusted period prevalence (%) | 0.06 | 0.04 | 0.08 |
| Median age at first event (years) | 68.20 | 64.48 | 70.70 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 264
- Matched controls
- 2639
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H43.2
ICD-10 Finland
Crystalline deposits in vitreous body
+∞
323.0
264
*
H43.3
ICD-10 Finland
Other vitreous opacities
234.6
40.0
40
*
H43.8
ICD-10 Finland
Other disorders of vitreous body
56.9
33.6
39
8
Z96.1
ICD-10 Finland
Presence of intraocular lens
5.8
29.2
97
240
CKD65
NOMESCO Finland
Pars plana or pars plicata vitrectomy
17.5
21.7
34
22
WX140
NOMESCO Finland
Parabulbar anesthesy
7.9
16.4
38
55
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
5.5
16.0
50
108
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
2.7
13.0
135
743
XCW99
NOMESCO Finland
Other investigative procedure of eye
3.6
11.4
55
180
A10AA01
ATC
NA
13.5
11.3
19
15
H26.4
ICD-10 Finland
After-cataract
3.8
11.2
49
148
A10AA02
ATC
NA
8.6
10.9
23
29
A10AB01
ATC
insulin (human); parenteral (insulins and analog. for injection, fast-acting)
8.0
10.4
23
31
H35.38
ICD-10 Finland
Preretinal fibrosis of the macula
7.2
10.2
24
36
E10.3
ICD-10 Finland
Type 1 diabetes mellitus, With ophthalmic complications
15.4
10.1
16
11
H25.1
ICD-10 Finland
Senile nuclear cataract
2.4
9.8
107
578
A10AB04
ATC
insulin lispro; parenteral (insulins and analog. for injection, fast-acting)
10.6
9.7
18
18
A10AE04
ATC
insulin glargine; parenteral
3.7
9.7
43
131
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)
2.3
9.2
122
724
CJB10
NOMESCO Finland
Laser discission of secondary cataract
3.6
9.0
42
133
CKD91
NOMESCO Finland
Extended vitrectomy through pars plana
14.7
8.8
14
10
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
9.5
8.7
17
19
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.4
8.5
89
467
H43.1
ICD-10 Finland
Vitreous haemorrhage
92.9
8.5
9
*
103
Kela drug reimbursment
Diabetes, insulin-treated
2.3
8.4
100
556
H36.00
ICD-10 Finland
Diabetic background retinopathy
12.2
8.2
14
12
H25.8
ICD-10 Finland
Other senile cataract
2.8
8.2
56
231
25000
ICD-8 Finland
Diabetes mellitus, Sine complicatione
7.5
7.6
17
24
H35.39
ICD-10 Finland
Degeneration of macula and posterior pole
5.1
7.0
21
44
H3600, E103
ICD-10 Finland
NA
23.2
6.7
9
*
H53.9
ICD-10 Finland
Visual disturbance, unspecified
7.2
6.6
15
22
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.5
6.6
30
94
H25.0
ICD-10 Finland
Senile incipient cataract
3.2
6.5
33
113
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.5
6.4
52
237
H36.09*E10.3
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic retinopathy
18.6
6.3
9
5
AA1AD
NOMESCO Finland
CT of head and brain
2.1
6.3
79
442
T89
ICPC
Diabetes insulin dependent
5.6
6.3
17
32
CKC12
NOMESCO Finland
Photocoagulation of retina
5.6
6.3
17
32
H52.1
ICD-10 Finland
Myopia
7.0
6.1
14
21
SPAT1262
SPAT
Handing over of treatment supplies
2.2
6.1
67
353
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
135
830
2.14
9.31
5.2
4.1
9.8
10.0
mg/mmol
0.01
83
517
139
928
1.93
7.10
2.3
2.2
78.8
75.9
nmol/l
0.50
120
811
88
527
1.95
6.04
1.9
1.7
1108.7
1178.6
nmol/l
0.30
65
397
252
2127
2.13
5.66
5.8
4.5
1.9
2.6
mu/l
0.60
227
1872
162
1192
1.78
5.63
6.0
4.1
0.0
0.0
estimate
0.50
26
206
75
443
1.92
5.29
1.4
1.2
0.7
1.4
u/ml
0.76
18
110
116
787
1.77
5.24
2.8
2.5
63.8
56.9
u/l
0.88
109
720
157
1161
1.74
5.23
5.9
4.1
0.0
0.0
estimate
0.00
27
220
158
1172
1.73
5.19
8.3
5.6
0.0
0.0
estimate
0.00
30
219
189
1479
1.75
5.08
10.3
5.1
7.3
6.9
mmol/l
1.60
180
1383
91
581
1.81
5.01
2.0
1.8
443.1
419.1
pmol/l
0.38
68
474
101
669
1.77
4.89
4.0
3.0
383.5
9262.8
umol/l
3.51
81
567
230
1916
1.85
4.88
8.7
8.1
79.2
80.9
u/l
0.23
217
1771
114
786
1.72
4.78
1.9
2.1
131.3
250.1
u/l
2.43
108
737
144
1059
1.69
4.75
5.6
4.1
40.9
69.8
ng/l
0.40
120
800
214
1754
1.76
4.69
4.8
4.3
15.1
13.8
mm/h
0.50
193
1590
274
2447
2.33
4.44
25.8
20.0
138.9
139.6
mmol/l
3.93
269
2375
207
1697
1.70
4.36
4.6
3.7
15.1
14.9
pmol/l
0.41
183
1490
274
2452
2.31
4.33
25.7
20.2
4.0
4.0
mmol/l
0.45
269
2381
274
2461
2.26
4.13
25.5
20.2
85.3
82.7
umol/l
0.77
274
2461
125
915
1.63
4.02
6.5
4.3
—
—
—
0
0
264
2345
2.02
4.00
6.1
5.4
2.4
2.6
mmol/l
2.24
237
2113
164
1284
1.61
3.99
7.2
7.0
1.2
1.2
mmol/l
0.20
134
1082
253
2222
1.87
3.89
9.1
6.5
43.8
40.9
mmol/mol
3.13
228
2031
30
141
2.25
3.86
3.1
2.8
1.4
1.1
%
0.71
30
141
33
163
2.15
3.77
4.8
3.7
1.6
2.2
mmol/l
0.48
26
124
23
97
2.48
3.75
2.2
1.7
—
—
—
0
0
148
1143
1.58
3.73
4.3
4.6
34.3
35.0
g/l
0.73
134
1064
22
92
2.50
3.65
3.5
4.0
35.8
35.2
mg/l
0.02
17
74
22
92
2.50
3.65
3.5
4.0
37.5
144.7
mg/l
0.87
16
73
139
1064
1.57
3.60
2.4
2.0
100.9
93.7
pmol/l
0.92
68
566
273
2478
2.09
3.52
13.0
11.5
25.0
25.0
u/l
0.01
262
2370
18
70
2.67
3.45
1.7
1.5
219.9
279.0
ug/g
0.63
11
40
257
2293
1.83
3.41
5.9
5.0
6.4
6.1
mmol/l
2.90
229
2049
77
517
1.66
3.41
5.7
4.6
1.0
1.0
kg/l
0.79
11
70
278
2550
2.18
3.32
31.7
24.7
132.6
134.2
g/l
0.84
273
2500
259
2321
1.83
3.32
22.2
16.9
30.3
26.2
mg/l
0.96
222
1888
256
2287
1.80
3.30
5.5
4.8
4.3
4.5
mmol/l
1.51
229
2072
91
644
1.59
3.24
6.0
4.3
0.0
0.0
estimate
0.00
26
211
31
159
2.06
3.23
2.1
1.4
—
—
—
0
0
254
2269
1.76
3.21
5.6
4.7
1.4
1.4
mmol/l
0.14
226
2037
23
105
2.29
3.18
2.2
1.9
—
—
—
0
0
13
44
3.04
3.17
3.6
2.8
4.0
4.1
mmol/l
0.11
13
44
13
44
3.04
3.17
3.6
2.8
104.2
105.7
mmol/l
0.43
13
44
120
912
1.53
3.10
3.7
3.2
1089.4
1462.2
ng/l
0.96
103
793
58
374
1.68
2.97
24.3
25.8
1.4
1.3
inr
—
5
49
247
2204
1.67
2.96
4.9
4.2
1.4
1.3
mmol/l
1.35
217
1967
175
1449
1.50
2.94
3.7
3.2
59.3
53.6
u/l
0.30
159
1334
91
668
1.52
2.70
1.7
1.6
25.2
20.2
nmol/l
1.61
73
553
124
973
1.47
2.65
5.2
3.3
—
—
—
0
0
38
227
1.77
2.55
3.5
3.1
4.5
4.3
kpa
0.32
38
215
164
1365
1.44
2.53
6.7
6.8
10.1
11.6
umol/l
1.98
156
1293
19
90
2.19
2.44
4.1
3.0
3.7
4.0
mmol/l
1.88
19
80
33
192
1.81
2.42
4.3
3.1
41.4
60.1
ml/min/173m2
—
7
81
7
17
4.19
2.37
7.3
2.1
49.2
52.8
u/ml
—
7
17
145
1190
1.42
2.36
7.0
6.1
1.2
1.2
mmol/l
0.01
126
1057
65
458
1.53
2.31
2.4
1.9
—
—
—
0
0
42
268
1.66
2.24
4.0
3.8
2.1
2.0
mmol/l
0.05
35
206
37
229
1.70
2.21
2.9
2.0
368.1
378.8
nmol/l
0.13
32
209
242
2197
1.52
2.18
19.5
16.0
70.6
74.8
ml/min/173m2
2.18
201
1826
42
271
1.64
2.15
4.0
3.8
5.7
5.8
kpa
0.16
42
260
229
2065
1.46
2.05
20.4
18.0
38.0
39.1
%
0.50
130
1331
49
336
1.55
1.96
1.4
1.3
21.7
8.9
u/ml
0.26
17
132
135
1121
1.37
1.94
5.4
5.4
2.9
2.9
ug/l
0.01
118
985
9
35
2.62
1.81
1.2
1.6
—
—
—
0
0
46
324
1.50
1.64
14.1
8.5
—
—
—
0
0
13
64
2.08
1.56
2.2
1.6
—
—
—
0
0
134
1142
1.31
1.53
4.5
4.1
—
—
—
0
0
158
1379
1.31
1.51
8.2
9.6
4.4
4.3
e9/l
0.34
140
1211
136
1164
1.31
1.49
2.9
2.6
—
—
—
0
0
96
785
1.33
1.46
2.8
3.4
29.3
30.7
u/l
0.25
86
744
5
16
3.16
1.44
1.2
1.9
—
—
—
0
0
42
299
1.47
1.43
2.9
4.7
21.8
46.4
ug/l
0.34
34
248
9
41
2.23
1.38
1.2
1.7
—
—
—
0
0
10
47
2.17
1.35
1.5
1.8
—
—
—
0
0
49
364
1.41
1.35
1.4
1.2
26.9
38.5
iu/ml
0.57
17
119
28
186
1.56
1.32
2.0
1.6
—
—
—
0
0
8
34
2.39
1.30
1.5
1.3
—
—
—
0
0
44
323
1.42
1.29
5.4
4.7
29.7
32.3
%
0.58
24
207
82
668
1.31
1.26
2.9
2.1
2.8
3.1
mg/l
0.65
70
570
90
748
1.29
1.19
5.0
3.2
0.3
0.5
e6/l
0.84
74
557
6
26
2.33
1.19
1.7
1.7
—
—
—
0
0
27
183
1.52
1.18
6.8
5.9
25.3
24.5
mmol/l
0.66
27
174
0
34
0.00
1.16
0.0
4.4
—
—
—
0
0
50
385
1.36
1.13
2.4
2.4
19.5
22.0
%
0.97
39
330
52
403
1.35
1.12
2.4
2.3
2.4
2.3
g/l
0.64
44
367
13
73
1.82
1.12
2.1
1.3
—
—
—
0
0
103
880
1.26
1.09
2.5
3.6
2.3
2.3
mmol/l
0.25
83
767
14
82
1.74
1.07
1.6
1.3
—
—
—
0
0
18
114
1.62
1.05
1.4
3.4
4.2
4.4
pmol/l
0.39
18
102
13
75
1.77
1.04
1.5
1.2
—
—
—
0
0
111
965
1.24
0.99
3.4
2.6
121.4
147.0
ug/l
0.76
97
875
10
54
1.88
0.97
1.4
1.4
—
—
—
0
0
43
332
1.34
0.96
4.7
6.7
1.5
1.5
mmol/l
0.06
37
267
0
32
0.00
0.95
0.0
1.2
—
7.4
—
0
20
9
52
1.75
0.93
1.3
1.7
—
—
—
0
0
13
78
1.70
0.93
2.8
2.6
345.6
82.0
ug/min
—
6
40
6
29
2.09
0.90
4.7
2.8
—
—
—
0
0
13
79
1.67
0.89
2.7
2.5
26.1
24.8
mmol/l
0.70
13
64
8
42
1.93
0.89
1.3
1.1
—
—
—
0
0
63
522
1.26
0.85
1.5
1.8
1.6
1.4
mg/l
0.10
47
417
16
235
0.66
0.83
3.3
2.4
26.1
32.9
u/l
0.92
16
189
13
81
1.63
0.82
1.2
1.0
—
—
—
0
0
10
58
1.75
0.80
1.8
1.2
—
—
—
0
0
10
58
1.75
0.80
1.8
1.2
—
—
—
0
0
11
66
1.69
0.79
1.4
1.7
—
—
—
0
0
76
649
1.23
0.79
1.9
1.6
1.4
1.3
mmol/l
0.56
54
528
17
116
1.49
0.76
3.7
2.7
7.4
7.4
g/l
—
10
89
17
116
1.49
0.76
3.7
2.7
5.5
3.6
g/l
—
9
84
17
116
1.49
0.76
3.7
2.7
—
—
—
0
0
40
318
1.30
0.76
2.3
1.9
—
—
—
0
0
61
512
1.24
0.75
5.5
3.9
138.2
340.2
ng/l
1.13
47
425
11
68
1.64
0.72
1.4
1.7
—
—
—
0
0
16
109
1.49
0.72
3.9
2.8
2.7
3.1
g/l
—
9
85
5
26
1.94
0.71
1.2
1.7
—
—
—
0
0
5
26
1.94
0.71
1.2
1.3
—
—
—
0
0
23
170
1.38
0.70
2.9
1.7
—
—
—
0
0
11
69
1.62
0.69
2.6
2.4
7.6
7.9
kpa
0.31
11
61
7
43
1.64
0.67
2.3
7.4
—
165.4
—
0
8
5
28
1.80
0.66
1.0
1.4
0.5
0.6
nmol/l
—
5
23
10
62
1.63
0.66
1.4
1.5
—
—
—
0
0
8
49
1.65
0.62
1.4
1.7
—
—
—
0
0
8
49
1.65
0.62
1.5
1.3
—
—
—
0
0
53
451
1.21
0.58
2.6
2.3
10.9
12.5
umol/l
1.08
46
409
70
612
1.19
0.58
2.4
2.4
—
—
—
0
0
20
262
0.75
0.58
1.6
1.4
—
—
—
0
0
34
276
1.26
0.57
5.5
7.3
116.6
120.8
g/l
0.67
34
270
6
37
1.63
0.56
1.0
1.1
—
—
—
0
0
6
38
1.59
0.54
1.5
1.3
—
—
—
0
0
13
92
1.43
0.51
2.8
3.2
—
—
—
0
0
7
46
1.53
0.48
1.4
1.7
—
—
—
0
0
26
210
1.26
0.47
2.1
1.8
2.2
1.6
%
1.16
20
173
5
33
1.52
0.41
1.2
1.7
—
—
—
0
0
0
16
0.00
0.41
0.0
1.9
—
—
—
0
0
0
16
0.00
0.41
0.0
1.9
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
14
106
1.34
0.40
1.4
2.1
156.9
335.9
ug/l
1.42
14
99
37
318
1.19
0.39
2.4
1.8
—
—
—
0
0
9
67
1.35
0.38
2.0
1.4
—
—
—
0
0
5
36
1.40
0.38
1.2
1.7
—
—
—
0
0
5
37
1.36
0.37
1.0
1.3
—
—
—
0
0
6
42
1.44
0.35
1.3
1.7
—
—
—
0
0
6
44
1.37
0.34
1.3
1.2
—
—
—
0
0
52
468
1.13
0.32
4.6
2.9
8.5
1.0
e6/l
0.47
37
270
96
897
1.10
0.31
4.8
4.7
21.8
21.5
%
0.08
54
469
49
444
1.12
0.27
5.0
3.2
1.5
1.9
e6/l
0.31
34
245
9
72
1.26
0.26
1.3
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
3.5
—
—
—
0
0
0
11
0.00
0.21
0.0
3.5
—
—
—
0
0
0
10
0.00
0.21
0.0
4.8
—
227.0
—
0
10
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
5
43
1.17
0.21
1.6
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
9
112
0.80
0.20
1.6
1.8
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
7
59
1.19
0.18
1.1
1.3
—
—
—
0
0
9
110
0.81
0.13
2.0
1.7
—
—
—
0
0
24
220
1.10
0.12
1.1
1.3
—
—
—
0
0
15
134
1.13
0.11
1.2
1.2
—
43.9
—
0
10
26
279
0.93
0.10
5.1
3.6
—
—
—
0
0
24
257
0.93
0.09
3.6
2.5
4.3
8.3
ug/l
1.58
18
224
6
70
0.85
0.07
1.5
2.7
3.7
3.8
g/l
—
6
65
6
70
0.85
0.07
1.7
1.5
166769.2
19901.4
e6/l
—
6
54
54
522
1.04
0.07
2.0
3.1
2.4
2.5
mmol/l
0.19
42
464
63
637
0.99
0.01
2.8
3.2
0.9
0.8
ug/l
0.13
43
447
0
7
0.00
0.00
0.0
2.6
—
13.2
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
9.3
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
6
68
0.88
0.00
2.7
1.9
—
—
—
0
0
0
8
0.00
0.00
0.0
8.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
101.3
—
0
8
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
6
59
1.02
0.00
1.2
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
5
0.00
0.00
0.0
3.2
—
140.6
—
0
5
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
4.0
—
112.0
—
0
5
9
98
0.92
0.00
1.6
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_VITRCRYSTAL and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_VITRCRYSTAL | 0.983 [0.8, 1.21] | 0.868 |
| Birth year | 0.996 [0.99, 1.0] | 0.342 |
During the follow-up period (1.1.1998 — 31.12.2019), 133 out of 603 females with H7_VITRCRYSTAL died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_VITRCRYSTAL | 0.981 [0.8, 1.2] | 0.852 |
| Birth year | 0.989 [0.98, 1.0] | 0.021 |
During the follow-up period (1.1.1998 — 31.12.2019), 251 out of 834 males with H7_VITRCRYSTAL died.
Mortality risk
Mortality risk for people of age
years, who have H7_VITRCRYSTAL.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.063% | 0.173% |
| 5 | 0.566% | 1.147% |
| 10 | 1.412% | 2.925% |
| 15 | 2.787% | 5.421% |
| 20 | 4.935% | 9.54% |
Relationships between endpoints
↥Index endpoint: H7_VITRCRYSTAL – Crystalline deposits in vitreous body
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data